552332-08-8

Upstream product

• 864770-82-1 1,1-dimethylethyl 3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole-1-carboxylate 
• 352704-97-3 5-[(S)-2-N-BOC-amino-3-phenyl-1-propyloxy]-2-chloro-3-bromo pyridine 

Downstream Products

• 864772-32-7 [(1S)-2-{[5-(3-methyl-1H-indazol-5-yl)-6-(1-methyl-1H-pyrrol-2-yl)-3-pyridinyl]oxy}-1-(phenylmethyl)ethyl]amine 
• 864771-01-7 {(S)-1-benzyl-2-[6-benzyl-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethyl}-carbamic acid benzyl ester 

Relevant academic research and scientific papers

2,3,5-Trisubstituted pyridines as selective AKT inhibitors-Part I: Substitution at 2-position of the core pyridine for ROCK1 selectivity

2,3,5-Trisubstituted pyridines have been designed as potent AKT inhibitors that are selective against ROCK1 based on the comparison between AKT and ROCK1 structures. Substitution at the 2-position of the core pyridine is the key element to provide selectivity against ROCK1. An X-ray co-crystal structure of 9p in PKA supports the proposed rationale of ROCK1 selectivity.

INHIBITORS OF AKT ACTIVITY

Invented are novel pyridine compounds, the use of such compounds as inhibitors of PKB/AKT kinase activity and in the treatment of cancer and arthritis.

Kinase inhibitors

Compounds having the formula are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.